Fecal Microbiota Transplantation in Colorectal Cancer: From Immune Regulation to Immunotherapy
- 1Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Ningbo University, Ningbo 315211, China
Abstract
The gut microbiome influences colorectal cancer (CRC) progression and responses to immune checkpoint inhibitors (ICIs), with immunotherapy resistance remaining a major challenge in microsatellite-stable/mismatch repair-proficient (MSS/pMMR) CRC. This review examines the mechanisms and translational potential of fecal microbiota transplantation (FMT) in CRC immunotherapy, focusing on the interplay among microbial functions, metabolic alterations, and immune microenvironment remodeling. Current evidence suggests that FMT may influence antitumor immunity beyond restoring microbial diversity by transferring functionally relevant microbial communities, metabolic profiles, and immunomodulatory signals. These changes may affect antigen presentation, inflammatory signaling, T-cell activity, and myeloid-cell states, thereby shaping the tumor immune microenvironment and potentially modulating responses to PD-1/PD-L1 blockade. However, the clinical efficacy of FMT in CRC, the determinants of successful microbial engraftment, and the mechanisms linking donor-derived microbial functions to therapeutic outcomes remain incompletely understood. Integrating defined microbial consortia, metabolite-based interventions, and multi-omics-guided patient stratification may help advance FMT toward mechanism-driven precision microbiome therapy and inform strategies to improve CRC immunotherapy outcomes.
Related
- The Gut Microbiota-Immunity Axis in Colorectal Cancer: Implications for Immunotherapy and Clinical Translation.
- Replacing animal-sourced with plant-sourced proteins alters gut microbiota and biomarkers associated with colorectal cancer risk in healthy adults: A randomized feeding study
- Lung microbiota, gut microbiota, and the lung-gut axis in lung cancer immunotherapy: a tripartite regulatory perspective
- Bariatric surgery-induced gut microbiota remodeling and innate immune activation: implications for gastrointestinal cancer immunotherapy
- The Interplay Between Obesity, Gut Microbiota and Early-onset Colorectal Cancer
BibTeX
@article{yang2026fecal,
title = {{Fecal Microbiota Transplantation in Colorectal Cancer: From Immune Regulation to Immunotherapy}},
author = {Xin Yang and Xiaoqin Ge and Shengping Gong and Ting Zhu and Chao Ni and Ruishuang Ma and Qingsong Tao},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18213426},
url = {https://www.mdpi.com/2072-6694/18/21/3426},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Fecal Microbiota Transplantation in Colorectal Cancer: From Immune Regulation to Immunotherapy
AU - Xin Yang
AU - Xiaoqin Ge
AU - Shengping Gong
AU - Ting Zhu
AU - Chao Ni
AU - Ruishuang Ma
AU - Qingsong Tao
PY - 2026
DA - 2026/10/22
JO - Cancers
DO - 10.3390/cancers18213426
UR - https://www.mdpi.com/2072-6694/18/21/3426
AB - The gut microbiome influences colorectal cancer (CRC) progression and responses to immune checkpoint inhibitors (ICIs), with immunotherapy resistance remaining a major challenge in microsatellite-stable/mismatch repair-proficient (MSS/pMMR) CRC. This review examines the mechanisms and translational potential of fecal microbiota transplantation (FMT) in CRC immunotherapy, focusing on the interplay among microbial functions, metabolic alterations, and immune microenvironment remodeling. Current evidence suggests that FMT may influence antitumor immunity beyond restoring microbial diversity by transferring functionally relevant microbial communities, metabolic profiles, and immunomodulatory signals. These changes may affect antigen presentation, inflammatory signaling, T-cell activity, and myeloid-cell states, thereby shaping the tumor immune microenvironment and potentially modulating responses to PD-1/PD-L1 blockade. However, the clinical efficacy of FMT in CRC, the determinants of successful microbial engraftment, and the mechanisms linking donor-derived microbial functions to therapeutic outcomes remain incompletely understood. Integrating defined microbial consortia, metabolite-based interventions, and multi-omics-guided patient stratification may help advance FMT toward mechanism-driven precision microbiome therapy and inform strategies to improve CRC immunotherapy outcomes.
SN - 2072-6694
ER -